Search

Displaying results 3401 - 3410 of 4600 in total
  1. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  2. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  3. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma

  4. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  5. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  6. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  7. Drug

    Debamestrocel

    go.drugbank.com/drugs/DB17934
    Investigational

    Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]

  8. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

  9. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand _ex vivo_.

    Synonyms: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo
  10. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...